Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Exploring New COVID-19 Incertitude: JN.1 Variant- JN.1: The Queer Bird Among Omicron Sublineages

In Press, (this is not the final "Version of Record"). Available online 27 June, 2024
Author(s): Suman Kumar Ray and Sukhes Mukherjee*
Published on: 27 June, 2024

Article ID: e270624231369

DOI: 10.2174/0118715265304215240530073446

Price: $95

Abstract

COVID-19 pandemic is casting a long shadow, and the appearance of the JN.1 variety calls attention to the necessity of maintaining heightened awareness. It considers the strength that has been developed via immunization programs and the necessity of global collaboration to find a solution in light of the emergence of new strains of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Phylogenetically, the SARS-CoV-2 Omicron XBB lineages, which include EG.5.1 and HK.3, are different from the SARS-CoV-2 BA.2.86 lineage, which was initially discovered in August 2023. More than 30 mutations in the spike (S) protein are carried by BA.2.86 compared to XBB and BA.2, suggesting a high potential for immune evasion. JN.1 (BA.2.86.1.1), a descendant of BA.2.86, appeared in late 2023 after the format had undergone evolution. JN.1 carries three mutations in proteins that do not include S, as well as S:L455S. As previously demonstrated, the HK.3 and other "FLip" variations possess the S:L455F mutation, which enhances transmissibility and immune escape capacity in comparison to the parental EG.5.1 variety. This mutation is a characteristic of JN.1. The COVID-19 virus is dynamic and evolves over time. New varieties can sometimes spread more quickly or effectively after these alterations. If that happens, the new variant has a chance to outpace the current varieties in terms of frequency.

[1]
Mahase E. COVID-19: New “Pirola” variant BA.2.86 continues to spread in UK and US. BMJ 2023; 382: p2097.
[http://dx.doi.org/10.1136/bmj.p2097] [PMID: 37704230]
[2]
Vinall F, Nirappil F. New coronavirus variant JN.1 is spreading fast. Here’s what to know. 2023. Available from: post.com/wellness/2023/12/20/new-covid-variant-jn1-symptoms/(Last accessed on January 13, 2024).
[3]
Roxby PJN. 1 COVID variant: WHO charts its rapid global spread. BBC News 2023. Available from: https://www.bbc.co.uk/news/health-67772390(Last accessed on January 13, 2024).
[4]
Looi MK. COVID-19: WHO adds JN.1 as new variant of interest. BMJ 2023; 383: p2975.
[http://dx.doi.org/10.1136/bmj.p2975] [PMID: 38128957]
[5]
Uriu K, Ito J, Kosugi Y. Transmissibility, infectivity, and immune 172 evasion of the SARS-CoV-2 BA.2.86 variant. Lancet Infect Dis 2023; 23(11): 173-4.
[6]
Wang Q, Guo Y, Liu L. Antigenicity and receptor affinity of 175 SARS-CoV-2 BA.2.86 spike. Nature 2023; 176.
[7]
Sheward DJ, Yang Y, Westerberg M, et al. Sensitivity of the SARS-CoV-2 BA.2.86 variant to prevailing neutralising antibody responses. Lancet Infect Dis 2023; 23(11): e462-3.
[http://dx.doi.org/10.1016/S1473-3099(23)00588-1] [PMID: 37776877]
[8]
Yang S, Yu Y, Jian F, et al. Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86. Lancet Infect Dis 2023; 23(11): e457-9.
[http://dx.doi.org/10.1016/S1473-3099(23)00573-X] [PMID: 37738994]
[9]
Kosugi Y, Plianchaisuk A, Putri O. Virological characteristics of the 182 SARS-CoV-2 Omicron HK.3 variant harboring the “FLip” substitution. BioRxiv 2023.
[http://dx.doi.org/10.1101/2023.11.14.566985]
[10]
Kaku Y, Okumura K, Padilla-Blanco M, et al. Virological characteristics of the SARS-CoV-2 JN.1 variant. Lancet Infect Dis 2024; S1473-3099.
[11]
Yamasoba D, Kimura I, Nasser H, et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike. Cell 2022; 185(12): 2103-2115.e19.
[http://dx.doi.org/10.1016/j.cell.2022.04.035] [PMID: 35568035]
[12]
Uriu K, Ito J, Zahradnik J. Enhanced transmissibility, infectivity, and 187 immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant. Lancet Infect Dis 2023; 23(3): 280-1.
[13]
Mukherjee S, Ray SK. A new wave of COVID-19 in 2021 with unique genetic characters - Present global scenario and beholding onwards. Infect Disord Drug Targets 2022; 22(6): e010422202932.
[http://dx.doi.org/10.2174/1871526522666220401101818] [PMID: 35366784]
[14]
Mukherjee S, Ray SK. Third wave of the COVID-19 pandemic: Prominence of initial public health interference. Infect Disord Drug Targets 2022; 22(4): e080222200919.
[http://dx.doi.org/10.2174/1871526522666220208115101] [PMID: 35135456]
[15]
Altamimi I, Alabdulkarim IM, Alhumimidi AS, Albabtain MA, Temsah MH. Navigating novel uncertainties of COVID-19: The rise of the JN.1 variant. Cureus 2024; 16(1): e51497.
[http://dx.doi.org/10.7759/cureus.51497] [PMID: 38304689]
[16]
GISAID. Available from: https://gisaid.org/hcov19-variants/(Last accessed on January 13, 2024).
[17]
Planas D, Staropoli I, Michel V, Lemoine F, Donati F, Prot M. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86 lineages combined increased fitness and antibody evasion. bioRxiv 2023.
[http://dx.doi.org/10.1101/2023.11.20.567873]
[18]
Wang Q, Guo Y, Bowen A, Mellis IA, Valdez R, Gherasim C. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants. bioRxiv 2023.
[http://dx.doi.org/10.1101/2023.11.26.568730]
[19]
World health organization technical advisory group on COVID-19 vaccine composition. Available from: https://www.who.int/news/item/13-12-2023-statement-on-the-antigen-composition-of-covid-19-vaccines(Last accessed on January 13, 2024).
[20]
World health organization technical advisory group on COVID-19 vaccine composition. Available from: https://www.who.int/news/item/18-05-2023-statement-on-the-antigen-composition-of-covid-19-vaccines (Last accessed on January 13, 2024).
[21]
Executive Summary. WHO. Available from: https://www.who.int/docs/default-source/coronaviruse/18122023_jn.1_ire_clean.pdf?sfvrsn=6103754a_3 (Last accessed on January 13, 2024).
[22]
EU4S-DEEP - Wastewater observatory for public health - Digital European exchange platform. Available from: https://wastewater-observatory.jrc.ec.europa.eu/#/gis-area/3(Last accessed on January 13, 2024).
[23]
Yang S, Yu Y, Xu Y, Jian F, Song W, Yisimayi A. Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure. bioRxiv 2023.
[http://dx.doi.org/10.1101/2023.11.13.566860]
[24]
Presentation at the WHO technical advisory group (TAG-VE) meeting on 11 December. Statens Serum Institut, Denmark 2023.
[25]
Presentation at the WHO Technical Advisory Group (TAG-VE) meeting on 11 December. Ministry of Health, Singapore 2023.
[26]
Variant proportions. CDC. 2023. Available from: https://covid.cdc.gov/covid-data-tracker/#variant(Last accessed on January 13, 2024).
[27]
Initial risk evaluation of BA.2.86 and its sublineages. 2023. Available from: https://www.who.int/docs/default source/coronaviruse/21112023_ba.2.86_ire.pdf?sfvrsn=8876def1_3(Last accessed on January 13, 2024).
[28]
World Health Organization 2024. Available from: https://www.who.int/docs/default-source/coronaviruse/15042024_jn1_ure.pdf?sfvrsn=8bd19a5c_7
[29]
Ray SK, Mukherjee S. From bench side to bed-travelling on a road to get a safe and effective vaccine against COVID-19, day to save the life. Recent Pat Biotechnol 2022; 16(1): 2-5.
[http://dx.doi.org/10.2174/1872208315666211209094457] [PMID: 34886784]
[30]
Ray SK, Mukherjee S. Immunological facet and inception after post-COVID-19 vaccination. Infect Disord Drug Targets 2023; 23(5): e060423215496.
[http://dx.doi.org/10.2174/1871526523666230406100146] [PMID: 37038664]
[31]
US centers for disease control and prevention. Variants happen. 2023. Available from: https://www.cdc.gov/respiratory-viruses/whats-new/variants-happen.html (Last accessed on January 13, 2024).

Rights & Permissions Print Cite
© 2025 Bentham Science Publishers | Privacy Policy